Interpace Diagnostics Group (NASDAQ:IDXG) and GenMark Diagnostics (NASDAQ:GNMK) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Valuation and Earnings

This table compares Interpace Diagnostics Group and GenMark Diagnostics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Interpace Diagnostics Group $15.90 million 2.89 -$12.21 million ($0.81) -2.01
GenMark Diagnostics $52.52 million 8.56 -$61.85 million ($1.21) -6.66

Interpace Diagnostics Group has higher earnings, but lower revenue than GenMark Diagnostics. GenMark Diagnostics is trading at a lower price-to-earnings ratio than Interpace Diagnostics Group, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Interpace Diagnostics Group has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500. Comparatively, GenMark Diagnostics has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500.

Insider and Institutional Ownership

12.5% of Interpace Diagnostics Group shares are owned by institutional investors. Comparatively, 99.5% of GenMark Diagnostics shares are owned by institutional investors. 2.8% of Interpace Diagnostics Group shares are owned by insiders. Comparatively, 7.1% of GenMark Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for Interpace Diagnostics Group and GenMark Diagnostics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Interpace Diagnostics Group 0 0 4 0 3.00
GenMark Diagnostics 0 1 4 0 2.80

Interpace Diagnostics Group presently has a consensus target price of $3.44, suggesting a potential upside of 110.89%. GenMark Diagnostics has a consensus target price of $10.50, suggesting a potential upside of 30.27%. Given Interpace Diagnostics Group’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Interpace Diagnostics Group is more favorable than GenMark Diagnostics.

Profitability

This table compares Interpace Diagnostics Group and GenMark Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Interpace Diagnostics Group -71.14% -34.58% -25.64%
GenMark Diagnostics -91.58% -87.96% -50.38%

Summary

Interpace Diagnostics Group beats GenMark Diagnostics on 9 of the 13 factors compared between the two stocks.

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. The company's customers consist primarily of physicians, hospitals, and clinics. The company was formerly known as PDI, Inc. and changed its name to Interpace Diagnostics Group, Inc. in December 2015. Interpace Diagnostics Group, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.